The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine years of age and older is Journey Medical’s seventh marketed dermatology product Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered into a definitive agreement to acquire QBREXZA (glycopyrronium) in the U.S. from Dermira, Inc., a wholly-owned…